<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Phys Ther Sci</journal-id><journal-id journal-id-type="iso-abbrev">J Phys Ther Sci</journal-id><journal-id journal-id-type="publisher-id">JPTS</journal-id><journal-title-group><journal-title>Journal of Physical Therapy Science</journal-title></journal-title-group><issn pub-type="ppub">0915-5287</issn><issn pub-type="epub">2187-5626</issn><publisher><publisher-name>The Society of Physical Therapy Science</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29581669</article-id><article-id pub-id-type="pmc">5857456</article-id><article-id pub-id-type="publisher-id">jpts-2017-313</article-id><article-id pub-id-type="doi">10.1589/jpts.30.448</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Comparision of the effectiveness of ESWT and ultrasound treatments in
myofascial pain syndrome: randomized, sham-controlled study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Akt&#x000fc;rk</surname><given-names>Semra</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref rid="cor1" ref-type="corresp"><sup>*</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kaya</surname><given-names>Arzu</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>&#x000c7;etinta&#x0015f;</surname><given-names>Derya</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Akg&#x000f6;l</surname><given-names>G&#x000fc;rkan</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>G&#x000fc;lkesen</surname><given-names>Arif</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kal</surname><given-names>G&#x000fc;l Ayden</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>G&#x000fc;&#x000e7;er</surname><given-names>T&#x000fc;lin</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><aff id="aff1"><label>1)</label> Department of Physical Medicine and Rehabilitation, Faculty
of Medicine, In&#x000f6;n&#x000fc; Univesity: Malatya, Turkey</aff><aff id="aff2"><label>2)</label> Faculty of Medicine, Department of Physical Medicine and
Rehabilitation, Faculty of Medicine, Faculty of Medicine, Turkey</aff><aff id="aff3"><label>3)</label> Department of Physical Medicine and Rehabilitation, Elaz&#x00131;&#x0011f;
Education and Research Hospital, Turkey</aff><aff id="aff4"><label>4)</label> Department of Physical Medicine and Rehabilitation, Anadolu
Hospital, Turkey</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Corresponding author. Semra Akt&#x000fc;rk (E-mail: <email xlink:href="semrakayakturk@hotmail.com">semrakayakturk@hotmail.com</email>)</corresp></author-notes><pub-date pub-type="epub"><day>2</day><month>3</month><year>2018</year></pub-date><pub-date pub-type="ppub"><month>3</month><year>2018</year></pub-date><volume>30</volume><issue>3</issue><fpage>448</fpage><lpage>453</lpage><history><date date-type="received"><day>14</day><month>6</month><year>2017</year></date><date date-type="accepted"><day>23</day><month>8</month><year>2017</year></date></history><permissions><copyright-statement>2018&#x000a9;by the Society of Physical Therapy Science. Published by IPEC
Inc.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><license-p>This is an open-access article distributed under the terms of the Creative
Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. (CC-BY-NC-ND 4.0:
<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>)</license-p></license></permissions><abstract><p>[Purpose] The purpose of this study is to compare effectiveness of extracorporeal shock
wave therapy (ESWT), ultrasound (US) and sham ESWT in the treatment of myofascial pain
syndrome (MPS). [Subjects and Methods] Sixty MPS patients aged 18&#x02013;60 years were included
in the study. The patients were randomized equally into 3 groups. Group 1 received ESWT
for 4 session with 3 day-intervals. Group 2 received 4 sessions of sham ESWT. US was
applied to Group 3 for 10 sessions. All patients were recommended an exercise program. The
patients were evaluated before-post and 6 weeks after treatment. Measurements were made
using pressure pain threshold (PPT), pain score (PS) and visual analogue scale (VAS).
Patients were evaluated by using SF-36 and HADS (hospital anxiety and depression scale).
[Results] A significant posttreatment difference was found in VAS, PPT and SF-36
subparameters in group 1. In group 2, a significant difference was not found in any
parameter. In group 3, a significant difference was detected in parameters of VAS and PPT.
A significant difference was found between groups 1 and 2 as for subtitles of PPT, VAS,
SF-36. [Conclusion] These results suggest that ESWT is as effective as US. ESWT and US are
significantly more effective than sham ESWT.</p></abstract><kwd-group><kwd>Myofascial pain syndrome</kwd><kwd>Ultrasound</kwd><kwd>Extracorporeal shock wave therapy</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>INTRODUCTION</title><p>Myofascial pain syndrome (MPS) is characterized with hypersensitive (also called) trigger
points found in muscles and/or fascias, pain, spasm, sensitivity, stiffness, fatigue and
occasionally autonomic dysfunctions<xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r3" ref-type="bibr">3</xref><sup>)</sup>.
Treatment in myofascial pain syndrome is generally targeted at trigger points. Medical
treatment and physical treatment modalities such as injection therapy, spray and traction
techniques, superficial hot and cold applications, ultrasound, massage and TENS are
effective in decreasing pain<xref rid="r4" ref-type="bibr">4</xref>, <xref rid="r5" ref-type="bibr">5</xref><sup>)</sup>. These modalities impair and inactivate trigger points with
their thermal or mechanic effects<xref rid="r4" ref-type="bibr">4</xref><sup>)</sup>.</p><p>Ultrasound is successfully used in the treatment of rheumatic and many muscle diseases.
Ultrasound applied at target points in MPS has achieved marked improvement in neck pain<xref rid="r5" ref-type="bibr">5</xref>, <xref rid="r6" ref-type="bibr">6</xref><sup>)</sup>.</p><p>Extracorporeal shock wave therapy is a noninvasive method used recently in the treatment of
musculoskeletal diseases. Many investigations have been performed concerning the
effectiveness of ESWT in various musculoskeletal diseases. Among them calcific
tendinopathies of rotator cuff, chronic plantar fasciitis, lateral and medial epicondylitis,
Achilles tendinopathies and painful heel spurs can be enumerated<xref rid="r7" ref-type="bibr">7</xref>,<xref rid="r8" ref-type="bibr">8</xref>,<xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref><sup>)</sup>. Various studies have
demonstrated effectiveness of radial or focused shock wave therapy in the treatment of
myofascial pain<xref rid="r11" ref-type="bibr">11</xref>,<xref rid="r12" ref-type="bibr">12</xref>,<xref rid="r13" ref-type="bibr">13</xref>,<xref rid="r14" ref-type="bibr">14</xref><sup>)</sup>.</p><p>In the present study, we aimed to compare effectiveness of a new physical therapy modality
ESWT and US; a standard therapy in the treatment of patients with MPS.</p></sec><sec sec-type="methods" id="s2"><title>SUBJECTS AND METHODS</title><p>Forty female and 20 male patients (total n=60) aged between 18&#x02013;60 years (mean age, 34.85 &#x000b1;
9.25&#x02005;years) who applied to the outpatient clinic of the Department of Physical Medicine and
Rehabilitation with diagnosis of myofascial pain syndrome which were determined according to
the criteria defined by Travel and Simons<xref rid="r2" ref-type="bibr">2</xref><sup>)</sup>. Patients whose disease persisted for at least 6 months, but didn&#x02019;t
receive any treatment for the previous 8 weeks were included in the study. Patients with
cardiovascular and/or respiratory system disease or any malignancy, those who received
injections at myofascial trigger points within the previous two months or underwent neck or
shoulder surgery within a year, individuals diagnosed as fibromyalgia, cervical
radiculopathy or myelopathy, pregnant women, acute trauma patients and persons with
cooperation deficits were excluded from the study.</p><p>The study was performed in compliance with principles of Helsinki Declaration and approval
of the local ethics committee was obtained.</p><p>Patients were referred to our study and evaluated for whether or not they met
inclusion/exclusion criteria. Patients who met inclusion/exclusion criteria were randomized
into three groups by pulling the envelopes by the order of admission to the outpatient
clinic.</p><p>Four sessions of ESWT were applied to Group 1, and sham ESWT was applied to Group 2
patients. US was applied to Group 3 patients. Twenty patients were included in each group.
Detailed physical examinations were performed and a standard evaluation form was completed
by all patients. All of the participant&#x02019;s age, gender, socioeconomic status, occupations,
exercise capacities, personal and family history findings were recorded.</p><p>A total of 4 sessions ESWT was performed using Storz medical masterpulse MP200 device
adjusted to following settings: 1.6&#x02212;3.0 bar, 200&#x02013;400 shocks/trigger point, total of
2,000&#x02212;3,000 shock/session, maximum 3&#x02005;min/session with at most 3 day intervals between
sessions. D20 transmitter (&#x000d8; 20&#x02005;mm) headpiece was used.</p><p>A total of 4 sessions sham ESWT 1.0&#x02212;1.3 bar for 3&#x02005;min/session, without application of shock
waves applied to second group.</p><p>Active continuous US treatment for 2 weeks for 5 days a week for a total of 10 sessions
each session lasting for 5 minutes at a dose of 1.5 w/cm<sup>2</sup> applied to third
group.</p><p>Treatments were performed by the same physiotherapist, on a wooden desk, between the hours
08:00 and 12:00 in a room at 24&#x000b0;C. All patients were evaluated by the same physiatrist
before the treatment (1. control) at the end of the treatment (2 weeks later) (2. control)
and four weeks after the treatment (3. control). Pressure pain threshold (PPT) was measured
using algometer developed by Fischer and pain score measurement was performed with digital
palpation. Measurements of pressure pain threshold was measured, by increasing the pressure
1&#x02005;kg/sec and the same site was examined for at most two times at one minute intervals. Pain
score (PS) was evaluated as the intensity of pain felt when nail bed was pressed manually
with a thumb till it whitens (nearly 4&#x02005;kg pressure) and scored between 0 and 3 points (0: no
pain, 1: mild pain, 2: marked pain, 3: severe pain making the patient to startle).</p><p>For evaluation of disability and efficacy of treatment before the treatment and at each
posttreatment control visits visual analogue scale (VAS) and SF-36 tests were performed. For
the evaluation of anxiety and depression related to chronic pain hospital anxiety and
depression scale (HADS) was performed at 1, and 3. control visits.</p><p>All patients were recommended an exercise program consisting of traction and isometric
exercises to be applied during treatment period at treatment unit and afterwards at home.
The program focused on daily gentle unresisted isometric cervical flexion, extension and
rotation exercises (about 3 sets of 10 repetitions of each exercise daily). Exercise was
then progressed in each direction with low isometric resistance, increasing the exercise
parameters toward 3 sets of 10 repetitions in supine and sitting positions. Stretching
exercises: while seated, the subject performed stretching exercises for the upper trapezius,
scalene, semispinal muscle of head and sternocleidomastoid muscles; each stretch for 25&#x02013;30
seconds.</p><p>Visual analogue scale (VAS) measures severity of patient&#x02019;s pain and its validation and
reliability studies have been performed. VAS scale evaluates patient&#x02019;s pain perception on a
scale of 10 vertical or horizontal lines from 0 (no pain) to 10 points (the most severe
pain)<xref rid="r15" ref-type="bibr">15</xref><sup>)</sup>.</p><p>Hospital anxiety and depression scale (HADS) is applied to determine the risk for anxiety
and depression and to measure their level and severity. It comprise a total of 14 questions
which measure anxiety and depression. The minimum and maximum scores to be obtained for
anxiety and depression are 0 and 21 points, respectively<xref rid="r16" ref-type="bibr">16</xref><sup>)</sup>.</p><p>Short Form-36 (SF-36) is the most frequently used generic quality of life scale in the
field of medicine and consists of 8 subscales with 36 items which evaluate physical and
mental health. These subscales include physical functioning (PF), difficulty in physical
role (DPR), pain, general health perceptions (GHP), vitality, social role functioning (SRF),
restriction of emotional role functioning (REF) and mental health (MH)<xref rid="r17" ref-type="bibr">17</xref><sup>)</sup>.</p><p>SPSS 15.0 was used for statistical analysis. Distribution of anthropometric and demographic
characteristics of all cases were performed using descriptive statistical methods. In
intragroup comparisons three measurements were performed namely before, immediately and one
month after the treatment. Firstly Friedman nonparametric variance analysis was done and
then the parameters deemed to be significant (p&#x0003c;0.05) were subjected to pairwise (1 vs.
2; 1 vs. 3 and 2 Vs. 3 measurements) comparisons using nonparametric Wilcoxon test. For
pairwise comparisons of multiple measurements (3 measurements) using Wilcoxon test in each
group limit of significance was accepted as 0.05/number of comparisons (3 comparisons)=0.16
(Bonferroni correction). For other comparisons limit of significance was accepted as 0.05.
For intergroup comparisons, priorly three groups were compared using nonparametric
Kruskal-Wallis test, then for intergroup comparisons of parameters which differed
significantly (p&#x0003c;0.05) nonparametric Mann-Whitney U test with Bonferroni correction was
used. For intergroup comparisons of ordinal and nominal variables &#x003c7;<sup>2</sup> test was
used. To this end in each group means of all numerical values of 1, 2 and 3 measurements
were subtracted from each other to obtain differences which were then compared between
groups using m-nonparametric Kruskal-Wallis test and for intergroup comparisons Mann-Whitney
U test was utilized.</p></sec><sec sec-type="results" id="s3"><title>RESULTS</title><p>A total of 60 patients (20 male and 40 female) aged 18&#x02013;60 years were enrolled in this
study. The mean age for the patient groups was 33.45 &#x000b1; 8.02, 35.45 &#x000b1; 8.07 and 35.65 &#x000b1;
11.03&#x02005;years, respectively. A significant intergroup difference was not found for demographic
characteristics, including gender, marital status, educational level of the patients among
the groups (p&#x002c3;0.05; <xref rid="tbl_001" ref-type="table">Table 1</xref><table-wrap id="tbl_001" orientation="portrait" position="float"><label>Table 1.</label><caption><title>Baseline characteristics of ESWT, Plasebo ESWT and US groups</title></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" align="left" rowspan="1"/><th align="center" rowspan="1" colspan="1">ESWT<break/>n (%)</th><th align="center" rowspan="1" colspan="1">Plasebo<break/>n (%)</th><th align="center" rowspan="1" colspan="1">US<break/>n (%)</th><th align="center" rowspan="1" colspan="1">Total<break/>n (%)</th></tr></thead><tbody><tr><td align="left" colspan="2" rowspan="1">Gender </td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">15 (75)</td><td align="center" rowspan="1" colspan="1">13 (65)</td><td align="center" rowspan="1" colspan="1">12 (60)</td><td align="center" rowspan="1" colspan="1">40 (66.7)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Male </td><td align="center" rowspan="1" colspan="1">5 (25)</td><td align="center" rowspan="1" colspan="1">7 (35)</td><td align="center" rowspan="1" colspan="1">8 (40)</td><td align="center" rowspan="1" colspan="1">20 (33.3)</td></tr><tr><td align="left" colspan="2" rowspan="1">Age </td><td align="center" rowspan="1" colspan="1">33.45 &#x000b1; 8.02</td><td align="center" rowspan="1" colspan="1">35.45 &#x000b1; 8.07</td><td align="center" rowspan="1" colspan="1">35.65 &#x000b1; 11.03</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="2" rowspan="1">Marital status</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Single </td><td align="center" rowspan="1" colspan="1">7 (35)</td><td align="center" rowspan="1" colspan="1">7 (35)</td><td align="center" rowspan="1" colspan="1">8 (36.7)</td><td align="center" rowspan="1" colspan="1">22 (36.7)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Married </td><td align="center" rowspan="1" colspan="1">13 (65)</td><td align="center" rowspan="1" colspan="1">13 (65)</td><td align="center" rowspan="1" colspan="1">12 (63.3)</td><td align="center" rowspan="1" colspan="1">48 (63.3)</td></tr><tr><td align="left" colspan="2" rowspan="1">Educational status</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Not literate</td><td align="center" rowspan="1" colspan="1">1 (5)</td><td align="center" rowspan="1" colspan="1">2 (10)</td><td align="center" rowspan="1" colspan="1">2 (10)</td><td align="center" rowspan="1" colspan="1">5 (8.3)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Elementary school</td><td align="center" rowspan="1" colspan="1">2 (10)</td><td align="center" rowspan="1" colspan="1">2 (10)</td><td align="center" rowspan="1" colspan="1">4 (20)</td><td align="center" rowspan="1" colspan="1">8 (13.3)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Secondary school</td><td align="center" rowspan="1" colspan="1">7 (35)</td><td align="center" rowspan="1" colspan="1">11 (55)</td><td align="center" rowspan="1" colspan="1">10 (50)</td><td align="center" rowspan="1" colspan="1">28 (46.7)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">University</td><td align="center" rowspan="1" colspan="1">10 (50)</td><td align="center" rowspan="1" colspan="1">5 (25)</td><td align="center" rowspan="1" colspan="1">4 (20)</td><td align="center" rowspan="1" colspan="1">19 (31.7)</td></tr><tr><td align="left" colspan="2" rowspan="1">Occupation</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Hard worker</td><td align="center" rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">1 (5)</td><td align="center" rowspan="1" colspan="1">1 (5)</td><td align="center" rowspan="1" colspan="1">2 (3.3)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Homemaker </td><td align="center" rowspan="1" colspan="1">12 (60)</td><td align="center" rowspan="1" colspan="1">9 (45)</td><td align="center" rowspan="1" colspan="1">12 (60)</td><td align="center" rowspan="1" colspan="1">33 (55)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Employed </td><td align="center" rowspan="1" colspan="1">1 (5)</td><td align="center" rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">1 (5)</td><td align="center" rowspan="1" colspan="1">2 (3.3)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Others </td><td align="center" rowspan="1" colspan="1">7 (35)</td><td align="center" rowspan="1" colspan="1">10 (50)</td><td align="center" rowspan="1" colspan="1">6 (30)</td><td align="center" rowspan="1" colspan="1">23 (38.3)</td></tr></tbody></table></table-wrap>). Distribution of pretreatment examination findings did not differ
significantly among groups.</p><p>Regarding pressure pain threshold values measured from trigger points did not differ
significantly between groups, while a significant difference was observed at the end of the
treatment, 2 and 6 weeks after treatment (p&#x002c2;0.05). Intergroup differences were detected
between ESWT-sham ESWT and US-sham ESWT groups in terms of trigger point pressure pain
threshold values estimated at 2 and 6 weeks after the treatment (p&#x002c2;0.05). However,
posttreatment PPT values between ESWT and US groups did not differ significantly (p&#x002c3;0.05)
(<xref rid="tbl_002" ref-type="table">Table 2</xref><table-wrap id="tbl_002" orientation="portrait" position="float"><label>Table 2.</label><caption><title>PPT, TPS and VAS parameters among ESWT, US and sham ESWT groups</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">a<break/>ESWT</th><th align="center" rowspan="1" colspan="1">b<break/>Sham ESWT</th><th align="center" rowspan="1" colspan="1">c<break/>US</th><th align="center" rowspan="1" colspan="1">a-b-c<break/>p<sup>&#x003c0;</sup></th><th align="center" rowspan="1" colspan="1">a-b<break/>p<sup>#</sup></th><th align="center" rowspan="1" colspan="1">a-c<break/>p<sup>#</sup></th><th align="center" rowspan="1" colspan="1">b-c<break/>p<sup>#</sup></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">PPT-I</td><td align="center" rowspan="1" colspan="1">2.41 &#x000b1; 0.70</td><td align="center" rowspan="1" colspan="1">2.20 &#x000b1; 0.73</td><td align="center" rowspan="1" colspan="1">2.55 &#x000b1; 0.59</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">PPT-II</td><td align="center" rowspan="1" colspan="1">3.44 &#x000b1; 0.89</td><td align="center" rowspan="1" colspan="1">2.30 &#x000b1; 0.80</td><td align="center" rowspan="1" colspan="1">3.20 &#x000b1; 0.71</td><td align="center" rowspan="1" colspan="1">**</td><td align="center" rowspan="1" colspan="1">**</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">*</td></tr><tr><td align="left" rowspan="1" colspan="1">PPT-III</td><td align="center" rowspan="1" colspan="1">4.43 &#x000b1; 1.15</td><td align="center" rowspan="1" colspan="1">2.25 &#x000b1; 0.85</td><td align="center" rowspan="1" colspan="1">3.89 &#x000b1; 0.99</td><td align="center" rowspan="1" colspan="1">**</td><td align="center" rowspan="1" colspan="1">**</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">**</td></tr><tr><td align="left" rowspan="1" colspan="1">TPS-I</td><td align="center" rowspan="1" colspan="1">2.50 &#x000b1; 0.51</td><td align="center" rowspan="1" colspan="1">2.40 &#x000b1; 0.59</td><td align="center" rowspan="1" colspan="1">2.45 &#x000b1; 0.51</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">TPS-II</td><td align="center" rowspan="1" colspan="1">1.65 &#x000b1; 0.74</td><td align="center" rowspan="1" colspan="1">2.35 &#x000b1; 0.58</td><td align="center" rowspan="1" colspan="1">1.80 &#x000b1; 0.52</td><td align="center" rowspan="1" colspan="1">*</td><td align="center" rowspan="1" colspan="1">*</td><td align="center" rowspan="1" colspan="1">*</td><td align="center" rowspan="1" colspan="1">*</td></tr><tr><td align="left" rowspan="1" colspan="1">TPS-III</td><td align="center" rowspan="1" colspan="1">1.20 &#x000b1; 0.50</td><td align="center" rowspan="1" colspan="1">2.35 &#x000b1; 0.58</td><td align="center" rowspan="1" colspan="1">1.45 &#x000b1; 0.51</td><td align="center" rowspan="1" colspan="1">**</td><td align="center" rowspan="1" colspan="1">**</td><td align="center" rowspan="1" colspan="1">*</td><td align="center" rowspan="1" colspan="1">**</td></tr><tr><td align="left" rowspan="1" colspan="1">VAS-I</td><td align="center" rowspan="1" colspan="1">6.29 &#x000b1; 1.81</td><td align="center" rowspan="1" colspan="1">6.60 &#x000b1; 1.39</td><td align="center" rowspan="1" colspan="1">7.31 &#x000b1; 1.15</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">VAS-II</td><td align="center" rowspan="1" colspan="1">4.76 &#x000b1; 1.98</td><td align="center" rowspan="1" colspan="1">6.71 &#x000b1; 1.23</td><td align="center" rowspan="1" colspan="1">6.24 &#x000b1; 1.13</td><td align="center" rowspan="1" colspan="1">*</td><td align="center" rowspan="1" colspan="1">*</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">*</td></tr><tr><td align="left" rowspan="1" colspan="1">VAS-III</td><td align="center" rowspan="1" colspan="1">4.01 &#x000b1; 1.78</td><td align="center" rowspan="1" colspan="1">6.87 &#x000b1; 1.39</td><td align="center" rowspan="1" colspan="1">5.29 &#x000b1; 1.32</td><td align="center" rowspan="1" colspan="1">**</td><td align="center" rowspan="1" colspan="1">**</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">*</td></tr></tbody></table><table-wrap-foot><p>PPT: Pressure pain threshold; TPS: Trigger point pain score; I: Before the treatment;
II: At the end of the treatment (2 weeks later); III: One month after the
treatment. &#x003c0;: Kruskall-Wallis test, <sup>#</sup>Mann-Whitney U test. *p&#x0003c;0.05, **p&#x0003c;0.01</p></table-wrap-foot></table-wrap>).</p><p>A significant difference was observed among these three groups in pain score values
estimated during palpitation of trigger points at 2 weeks and 1 month after the treatment.
Trigger point pain scores estimated immediately, 2 and 6 weeks after treatment differed
significantly between ESWT vs. sham ESWT and US groups in favour of the ESWT. In other
words, treatment effectiveness on trigger point pain score was higher in the ESWT and US
groups relative to sham ESWT group (<xref rid="tbl_002" ref-type="table">Table
2</xref>).</p><p>A significant intergroup difference was found in pain scores measured at the end of the
treatment and 6 posttreatment weeks using VAS. In pairwise comparisons a significant
difference was seen between ESWT and sham ESWT groups at the end of the treatment, besides
at control visits performed at 6 weeks of the treatment a significant difference was
obtained between ESWT-sham ESWT and US-sham ESWT groups (p&#x002c2;0.05).</p><p>In inquiries performed using short form-36, evaluations made one month after the treatment
detected significant differences among 3 groups in subscales of pain and physical
functioning (PF). In pairwise comparisons, a significant difference was observed between
ESWT-sham ESWT and US-sham ESWT groups as for pain parameter (p&#x002c2;0.05, <xref rid="tbl_003" ref-type="table">Table 3</xref><table-wrap id="tbl_003" orientation="portrait" position="float"><label>Table 3.</label><caption><title>Comparing pretreatment and posttreatment parametres of SF-36 and HADS among
groups</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">A<break/>ESWT</th><th align="center" rowspan="1" colspan="1">B<break/>sham ESWT</th><th align="center" rowspan="1" colspan="1">C<break/>US</th><th align="center" rowspan="1" colspan="1">a-b-c<break/>p<sup>&#x003c0;</sup></th><th align="center" rowspan="1" colspan="1">b<break/>p<sup>#</sup></th><th align="center" rowspan="1" colspan="1">c<break/>p<sup>#</sup></th><th align="center" rowspan="1" colspan="1">c<break/>p<sup>#</sup></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">SF-36 GH</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Beginnig</td><td align="center" rowspan="1" colspan="1">51.65 &#x000b1; 15.05</td><td align="center" rowspan="1" colspan="1">46.45 &#x000b1; 15.76</td><td align="center" rowspan="1" colspan="1">46.95 &#x000b1; 13.85</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2 week</td><td align="center" rowspan="1" colspan="1">53.00 &#x000b1; 13.61</td><td align="center" rowspan="1" colspan="1">47.20 &#x000b1; 11.17</td><td align="center" rowspan="1" colspan="1">47.35 &#x000b1; 13.66</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">6 week</td><td align="center" rowspan="1" colspan="1">55.25 &#x000b1; 12.76</td><td align="center" rowspan="1" colspan="1">44.95 &#x000b1; 12.48</td><td align="center" rowspan="1" colspan="1">49.20 &#x000b1; 12.94</td><td align="center" rowspan="1" colspan="1">*</td><td align="center" rowspan="1" colspan="1">*</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">*</td></tr><tr><td align="left" rowspan="1" colspan="1">SF-36 PF</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Beginning</td><td align="center" rowspan="1" colspan="1">68.75 &#x000b1; 17.46</td><td align="center" rowspan="1" colspan="1">54.75 &#x000b1; 20.935</td><td align="center" rowspan="1" colspan="1">55.25 &#x000b1; 19.36</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2 week</td><td align="center" rowspan="1" colspan="1">69.25 &#x000b1; 19.34</td><td align="center" rowspan="1" colspan="1">4.75 &#x000b1; 20.93</td><td align="center" rowspan="1" colspan="1">57.00 &#x000b1; 17.35</td><td align="center" rowspan="1" colspan="1">*</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">6 week</td><td align="center" rowspan="1" colspan="1">75.50 &#x000b1; 13.06</td><td align="center" rowspan="1" colspan="1">53 &#x000b1; 19.82</td><td align="center" rowspan="1" colspan="1">61.75 &#x000b1; 21.04</td><td align="center" rowspan="1" colspan="1">*</td><td align="center" rowspan="1" colspan="1">*</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">SF-36 Pain</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Beginning</td><td align="center" rowspan="1" colspan="1">41.10 &#x000b1; 12.27</td><td align="center" rowspan="1" colspan="1">39.65 &#x000b1; 6.59</td><td align="center" rowspan="1" colspan="1">39.65 &#x000b1; 10.12</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2 week</td><td align="center" rowspan="1" colspan="1">48.25 &#x000b1; 14.24</td><td align="center" rowspan="1" colspan="1">39.65 &#x000b1; 6.59</td><td align="center" rowspan="1" colspan="1">43.15 &#x000b1; 12.67</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">6 week</td><td align="center" rowspan="1" colspan="1">56.80 &#x000b1; 12.64</td><td align="center" rowspan="1" colspan="1">36.20 &#x000b1; 6.81</td><td align="center" rowspan="1" colspan="1">49.95 &#x000b1; 9.64</td><td align="center" rowspan="1" colspan="1">*</td><td align="center" rowspan="1" colspan="1">*</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">*</td></tr><tr><td align="left" rowspan="1" colspan="1">SF-36 DPR</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Beginning</td><td align="center" rowspan="1" colspan="1">20.00 &#x000b1; 34.98</td><td align="center" rowspan="1" colspan="1">17.05 &#x000b1; 31.51</td><td align="center" rowspan="1" colspan="1">32.50 &#x000b1; 36.34</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2 week</td><td align="center" rowspan="1" colspan="1">37.50 &#x000b1; 40.95</td><td align="center" rowspan="1" colspan="1">20.00 &#x000b1; 32.03</td><td align="center" rowspan="1" colspan="1">36.25 &#x000b1; 37.58</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">6 week</td><td align="center" rowspan="1" colspan="1">58.75 &#x000b1; 37.41</td><td align="center" rowspan="1" colspan="1">18.75 &#x000b1; 31.28</td><td align="center" rowspan="1" colspan="1">47.50 &#x000b1; 34.31</td><td align="center" rowspan="1" colspan="1">*</td><td align="center" rowspan="1" colspan="1">*</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">*</td></tr><tr><td align="left" rowspan="1" colspan="1">HADS</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Anxiety-I</td><td align="center" rowspan="1" colspan="1">6.80 &#x000b1; 2.76</td><td align="center" rowspan="1" colspan="1">8.15 &#x000b1; 4.01</td><td align="center" rowspan="1" colspan="1">6.55 &#x000b1; 4.92</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Anxiety-II</td><td align="center" rowspan="1" colspan="1">6.55 &#x000b1; 2.64</td><td align="center" rowspan="1" colspan="1">8.0 &#x000b1; 4.0</td><td align="center" rowspan="1" colspan="1">6.25 &#x000b1; 4.95</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Depression-I</td><td align="center" rowspan="1" colspan="1">5.30 &#x000b1; 3.62</td><td align="center" rowspan="1" colspan="1">7.50 &#x000b1; 4.34</td><td align="center" rowspan="1" colspan="1">5.75 &#x000b1; 4.59</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Depression-II</td><td align="center" rowspan="1" colspan="1">5.25 &#x000b1; 3.66</td><td align="center" rowspan="1" colspan="1">7.95 &#x000b1; 4.63</td><td align="center" rowspan="1" colspan="1">5.80 &#x000b1; 4.67</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p>I: Before the treatment; II: One month after the treatment (6 week); GH: General
health perceptions; PF: Physical functioning; DPR: Difficulty in physical role. <sup>&#x003c0;</sup>Kruskall-Wallis test, <sup>#</sup>Mann-Whitney U test. *p&#x0003c;0.05</p></table-wrap-foot></table-wrap>).</p><p>Pretreatment and posttreatment 2 and 6 week scores of HAD scale which evaluate states of
anxiety and depression did not differ significantly among three groups (p&#x002c3;0.05).</p></sec><sec sec-type="discussion" id="s4"><title>DISCUSSION</title><p>In our study we have observed marked therapeutic effectiveness on myofascial pain syndrome
in both ESWT and US. Besides, superiority of both ESWT and US over sham ESWT was seen.</p><p>US is a non-invasive treatment method that is often preferred for its thermal and
biophysical effects. Heat is the most important and most well-known effect of US. Analgesic
effect of US can be explained by various mechanisms. The main two mechanisms include
increase in blood flow due to dilatation of blood vessels as a result of metabolic
alterations secondary to thermal effect of US, decreased formation and removal of algesic
substances due to accelerated substance exchange between the capillary wall and cell
membranes, and more rapid tissue processing and permanent analgesia secondary to
improvement. US has been widely used in the treatment of musculoskeletal diseases for more
than sixty years. However, there are some disadvantages due to heat effect. Except for the
general contraindications of heat, US is not applied to fluid-filled organs, especially the
heart, eyes and pregnant uterus<xref rid="r18" ref-type="bibr">18</xref><sup>)</sup>.</p><p>US has been used for a long time with proven effectiveness and its effectiveness in the
treatment of myofascial pain syndrome has been demonstrated in many studies<xref rid="r19" ref-type="bibr">19</xref>, <xref rid="r20" ref-type="bibr">20</xref><sup>)</sup>. Esenyel et al. investigated the effectiveness of ultrasound and
injection treatment combined with exercise at trigger points on upper part of the trapezius
muscle and detected their equivalent effectiveness<xref rid="r21" ref-type="bibr">21</xref><sup>)</sup>. K&#x00131;sao&#x0011f;lu et al. evaluated pain using VAS and pressure pain
threshold and detected significant drop in VAS values and significant increase in pressure
pain threshold values after the treatment performed with ultrasound targeted at trigger
points in MPS<xref rid="r5" ref-type="bibr">5</xref><sup>)</sup>. However, Draper et al.
compared effectiveness of US and placebo US and demonstrated that US decreased stiffness of
latent trigger points and achieved a marked pain relief in patients<xref rid="r22" ref-type="bibr">22</xref><sup>)</sup>.</p><p>Similar to previous studies, in our study we observed significant improvement in PPT, VAS
and AS values at the end of the treatment in the US treatment group. A significant
difference was observed in the subscales of GH, DPR and SRF of SF-36 measured before and 2
and 6 weeks after treatment. A significant difference was detected in pain parameter of
SF-36 values estimated 2 and 6 weeks after treatment relative to pretreatment values and a
marked improvement was observed in posttreatment values.</p><p>As demonstrated in various studies, radial or focused shock wave treatment has been
successfully applied with a wide indication in the treatment of myofascial pain. Gleitz
indicated that ESWT is a novel and effective treatment modality in refractory cases with
MPS. They have shown that especially focused ESWT has an energy penetration capability of
nearly 5&#x02013;10&#x02005;cm and it is reliable in the prevention of referred pain<xref rid="r11" ref-type="bibr">11</xref><sup>)</sup>.</p><p>In a study encompassing 30 patients, M&#x000fc;ller et al. used focused ESWT and measured pain
response in MPS. They evaluated VAS before and 3 months after the treatment and indicated
that focused ESWT was effective in the diagnosis and treatment of the disease<xref rid="r23" ref-type="bibr">23</xref><sup>)</sup>. Similarly, we also detected a significant
difference between PPT, VAS and AS scores estimated before and 2 and 6 weeks after the
treatment in the ESWT group, while a prominent improvement was seen in posttreatment values
relative to pretreatment estimates. G&#x000fc;r et al. performed a study with 108 patients and
applied ESWT for one or three sessions and observed posttreatment decrease in trigger points
and improvement in anxiety scale scores in both groups. While in the group which received 3
sessions of ESWT they noticed decrease in pain scores 3 weeks after the treatment<xref rid="r12" ref-type="bibr">12</xref><sup>)</sup>. We also found significant difference in
intergroup comparisons of pain parameter of the SF-36 scores. In another study, ESWT was
compared with TENS and trigger point injection and ESWT was reported to be as effective as
TENS and trigger point injection on VAS scores<xref rid="r13" ref-type="bibr">13</xref><sup>)</sup>. Additionally, in our study significant improvements were obtained
in many parameters of SF-36 (AS, VAS, PPT, pain, physical functioning, social functioning,
difficulty in physical role) in both ESWT and US groups.</p><p>In a study, focused ESWT was compared with placebo and in the ESWT group, a marked
improvement was observed in VAS, algometer measurements and SF-36 scores calculated 3 months
later<xref rid="r14" ref-type="bibr">14</xref><sup>)</sup>. Also in our study, a
significant change was not detected in VAS, AS, PPT scores and none of the parameters of
SF-36 of the patients in the sham ESWT group. Posttreatment differences obtained in all
parameters were examined so as to determine the group with more prominent changes and then
intergroup comparisons were performed. Any significant difference between ESWT and US was
not found regarding any parameter. Based on this outcome we can say that ESWT and US have
similar efficacies in the treatment of MPS.</p><p>There are no suggested ideal dosages, number of shocks, durations of treatment or treatment
regimens of ESWT in trigger points; however, the common approach is to use ESWT at a low
dosage and with short durations in pathologies of soft tissues. In this study we applied
ESWT at low dosages in accordance with the literature.</p><p>The shock waves used in ESWT have mechanical and cellular effects. Transient injury or
increased permeability in cellular membranes of neurons is the most important effect. These
mechanisms may be explained by the analgesic effect of ESWT. Biological effects of ESWT also
include its effects on specific growth factors<xref rid="r24" ref-type="bibr">24</xref><sup>)</sup>. Neovascularization and cellular regeneration is also accelerated
in the tissue<xref rid="r25" ref-type="bibr">25</xref><sup>)</sup>. On the other hand, shock
waves can destroy cells by means of free radicals. Structural changes occurring within the
cytoplasm and the mitochondria, with an energy flux density of 0.5&#x02005;mJ/mm<sup>2</sup>, have
been demonstrated in electron microscopic studies. Some adverse effects might occur during
treatment like pain, haematoma, migraine attacks, feeling dizziness, sensitivity and
irritation of the tissues. In addition, petechiae, bleeding and haematomas might be seen.
Acute soft tissue infections, malignomas, pregnancy, epilepsy and blood coagulation diseases
are some of the contraindications<xref rid="r26" ref-type="bibr">26</xref>, <xref rid="r27" ref-type="bibr">27</xref><sup>)</sup>.</p><p>The main disadvantage of ESWT is that no valid therapy schemes yet exist. Our study has
demonstrated that four sessions of ESWT treatment is effective as US on the treatment of
myofascial pain syndrome and decrease clinical manifestations together with symptoms.</p><p>A limitation of our study is that our study population contained small number of patients,
larger patient groups should be studied to generalize the results. Additionally, we were not
able to evaluate the effects of ESWT on tissues in MPS.</p><p>In conclusion, all of these findings suggest that as a new treatment in MPS, ESWT is an
effective and safe treatment modality. ESWT may satisfy further advantage with respect to
requiring less time and fewer sessions. However, larger-scale studies which will demonstrate
effectiveness of ESWT are needed.</p><sec><title>Conflict of interest</title><p>None.</p></sec></sec></body><back><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group><name><surname>Alvarez</surname><given-names>DJ</given-names></name><name><surname>Rockwell</surname><given-names>PG</given-names></name></person-group>: <article-title>Trigger points: diagnosis and management</article-title>.
<source>Am Fam Physician</source>, <year>2002</year>, <volume>65</volume>:
<fpage>653</fpage>&#x02013;<lpage>660</lpage>. <pub-id pub-id-type="pmid">11871683</pub-id></mixed-citation></ref><ref id="r2"><label>2</label><mixed-citation publication-type="book"><person-group><name><surname>Travell</surname><given-names>JG</given-names></name><name><surname>Simons</surname><given-names>DG</given-names></name></person-group>: Myofascial pain and dysfunction. The trigger point manual. Baltimore:
Williams and Wilkins, <year>1992</year>, pp 5&#x02013;201.</mixed-citation></ref><ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group><name><surname>Borg-Stein</surname><given-names>J</given-names></name><name><surname>Simons</surname><given-names>DG</given-names></name></person-group>: <article-title>Focused review: myofascial pain</article-title>.
<source>Arch Phys Med Rehabil</source>, <year>2002</year>, <volume>83</volume>:
<fpage>S40</fpage>&#x02013;<lpage>S47, S48&#x02013;S49</lpage>. <pub-id pub-id-type="pmid">11973695</pub-id></mixed-citation></ref><ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group><name><surname>Lavelle</surname><given-names>ED</given-names></name><name><surname>Lavelle</surname><given-names>W</given-names></name><name><surname>Smith</surname><given-names>HS</given-names></name></person-group>: <article-title>Myofascial trigger points</article-title>. <source>Med
Clin North Am</source>, <year>2007</year>, <volume>91</volume>:
<fpage>229</fpage>&#x02013;<lpage>239</lpage>. <pub-id pub-id-type="pmid">17321283</pub-id></mixed-citation></ref><ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group><name><surname>van der Windt</surname><given-names>DA</given-names></name><name><surname>van der Heijden</surname><given-names>GJ</given-names></name><name><surname>van den Berg</surname><given-names>SG</given-names></name><etal>et al.</etal></person-group>: <article-title>Ultrasound therapy for musculoskeletal disorders: a
systematic review</article-title>. <source>Pain</source>, <year>1999</year>,
<volume>81</volume>: <fpage>257</fpage>&#x02013;<lpage>271</lpage>. <pub-id pub-id-type="pmid">10431713</pub-id></mixed-citation></ref><ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group><name><surname>Ay</surname><given-names>S</given-names></name><name><surname>Do&#x0011f;an</surname><given-names>SK</given-names></name><name><surname>Evcik</surname><given-names>D</given-names></name><etal>et al.</etal></person-group>: <article-title>Comparison the efficacy of phonophoresis and ultrasound
therapy in myofascial pain syndrome</article-title>. <source>Rheumatol Int</source>,
<year>2011</year>, <volume>31</volume>: <fpage>1203</fpage>&#x02013;<lpage>1208</lpage>.
<pub-id pub-id-type="pmid">20354859</pub-id></mixed-citation></ref><ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group><name><surname>Pan</surname><given-names>PJ</given-names></name><name><surname>Chou</surname><given-names>CL</given-names></name><name><surname>Chiou</surname><given-names>HJ</given-names></name><etal>et al.</etal></person-group>: <article-title>Extracorporeal shock wave therapy for chronic calcific
tendinitis of the shoulders: a functional and sonographic study</article-title>.
<source>Arch Phys Med Rehabil</source>, <year>2003</year>, <volume>84</volume>:
<fpage>988</fpage>&#x02013;<lpage>993</lpage>. <pub-id pub-id-type="pmid">12881822</pub-id></mixed-citation></ref><ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group><name><surname>Perlick</surname><given-names>L</given-names></name><name><surname>Schiffmann</surname><given-names>R</given-names></name><name><surname>Kraft</surname><given-names>CN</given-names></name><etal>et al.</etal></person-group>: <article-title>[Extracorporal shock wave treatment of the achilles
tendinitis: experimental and preliminary clinical results]</article-title>. <source>Z
Orthop Ihre Grenzgeb</source>, <year>2002</year>, <volume>140</volume>:
<fpage>275</fpage>&#x02013;<lpage>280</lpage> (in German). <pub-id pub-id-type="pmid">12085292</pub-id></mixed-citation></ref><ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group><name><surname>Krischek</surname><given-names>O</given-names></name><name><surname>Rompe</surname><given-names>JD</given-names></name><name><surname>Herbsthofer</surname><given-names>B</given-names></name><etal>et al.</etal></person-group>: <article-title>[Symptomatic low-energy shockwave therapy in heel pain and
radiologically detected plantar heel spur]</article-title>. <source>Z Orthop Ihre
Grenzgeb</source>, <year>1998</year>, <volume>136</volume>:
<fpage>169</fpage>&#x02013;<lpage>174</lpage> (in German). <pub-id pub-id-type="pmid">9615981</pub-id></mixed-citation></ref><ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group><name><surname>Rompe</surname><given-names>JD</given-names></name><name><surname>Rumler</surname><given-names>F</given-names></name><name><surname>Hopf</surname><given-names>C</given-names></name><etal>et al.</etal></person-group>: <article-title>Extracorporal shock wave therapy for calcifying tendinitis
of the shoulder</article-title>. <source>Clin Orthop Relat Res</source>,
<year>1995</year>, (<issue>321</issue>): <fpage>196</fpage>&#x02013;<lpage>201</lpage>.
<pub-id pub-id-type="pmid">7497669</pub-id></mixed-citation></ref><ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group><name><surname>Gleitz</surname><given-names>M</given-names></name></person-group>: <article-title>Trigger shockwave therapy with radial and focused
shockwaves</article-title>. <source>Current Status Orthop</source>, <year>2006</year>,
<volume>5</volume>: <fpage>303</fpage>&#x02013;<lpage>312</lpage>.</mixed-citation></ref><ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group><name><surname>G&#x000fc;r</surname><given-names>A</given-names></name><name><surname>Koca</surname><given-names>&#x00130;</given-names></name><name><surname>Karag&#x000fc;ll&#x000fc;</surname><given-names>H</given-names></name><etal>et al.</etal></person-group>: <article-title>Comparision of the effectiveness of two different
extracorporeal shockwave therapy regimens in the treatment of patients with myofascial
pain syndrome</article-title>. <source>Arch Rheumatol</source>, <year>2014</year>,
<volume>29</volume>: <fpage>186</fpage>&#x02013;<lpage>193</lpage>.</mixed-citation></ref><ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group><name><surname>Jeon</surname><given-names>JH</given-names></name><name><surname>Jung</surname><given-names>YJ</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><etal>et al.</etal></person-group>: <article-title>The effect of extracorporeal shock wave therapy on
myofascial pain syndrome</article-title>. <source>Ann Rehabil Med</source>,
<year>2012</year>, <volume>36</volume>: <fpage>665</fpage>&#x02013;<lpage>674</lpage>.
<pub-id pub-id-type="pmid">23185731</pub-id></mixed-citation></ref><ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group><name><surname>Ramon</surname><given-names>S</given-names></name><name><surname>Gleitz</surname><given-names>M</given-names></name><name><surname>Hernandez</surname><given-names>L</given-names></name><etal>et al.</etal></person-group>: <article-title>Update on the efficacy of extracorporeal shockwave
treatment for myofascial pain syndrome and fibromyalgia</article-title>. <source>Int J
Surg</source>, <year>2015</year>, <volume>24</volume>:
<fpage>201</fpage>&#x02013;<lpage>206</lpage>. <pub-id pub-id-type="pmid">26363497</pub-id></mixed-citation></ref><ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group><name><surname>Price</surname><given-names>DD</given-names></name><name><surname>McGrath</surname><given-names>PA</given-names></name><name><surname>Rafii</surname><given-names>A</given-names></name><etal>et al.</etal></person-group>: <article-title>The validation of visual analogue scales as ratio scale
measures for chronic and experimental pain</article-title>. <source>Pain</source>,
<year>1983</year>, <volume>17</volume>: <fpage>45</fpage>&#x02013;<lpage>56</lpage>.
<pub-id pub-id-type="pmid">6226917</pub-id></mixed-citation></ref><ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group><name><surname>Aydemir</surname><given-names>&#x000d6;</given-names></name><name><surname>G&#x000fc;venir</surname><given-names>T</given-names></name><name><surname>K&#x000fc;ey</surname><given-names>L</given-names></name><etal>et al.</etal></person-group>: <article-title>Hastane anksiyete ve depresyon &#x000f6;l&#x000e7;e&#x0011f;i T&#x000fc;rk&#x000e7;e formunun
ge&#x000e7;erlilik ve g&#x000fc;venilirli&#x0011f;i</article-title>. <source>Turk Psikiyatr Derg</source>,
<year>1977</year>, <volume>8</volume>:
<fpage>280</fpage>&#x02013;<lpage>287</lpage>.</mixed-citation></ref><ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group><name><surname>Ko&#x000e7;yigit</surname><given-names>H</given-names></name><etal>et al.</etal></person-group>: <article-title>SF-36&#x02019;nin Turkce icin guvenilirligi ve
ge&#x000e7;erlili&#x0011f;i</article-title>. <source>Ege Fiz Ted Reh Derg</source>, <year>1999</year>,
<volume>12</volume>: <fpage>102</fpage>&#x02013;<lpage>106</lpage>.</mixed-citation></ref><ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group><name><surname>Currier</surname><given-names>DP</given-names></name><name><surname>Kramer</surname><given-names>JF</given-names></name></person-group>: <article-title>Sensory nerve conduction: heating effects of ultrasound
and infrared</article-title>. <source>Physiother Can</source>, <year>1982</year>,
<volume>34</volume>: <fpage>241</fpage>&#x02013;<lpage>246</lpage>.</mixed-citation></ref><ref id="r19"><label>19</label><mixed-citation publication-type="book"><person-group><name><surname>Friction</surname><given-names>JR</given-names></name></person-group>: Myofascial pain syndrome characteristics and epidemiology. In: James R.
Frictionand Essam Awad, eds. Advances in pain research and therapy. Raven Press,
<year>1990</year>, pp 107&#x02013;125.</mixed-citation></ref><ref id="r20"><label>20</label><mixed-citation publication-type="journal"><person-group><name><surname>Hsieh</surname><given-names>YL</given-names></name></person-group>: <article-title>Effects of ultrasound and diclofenac phonophoresis on
inflammatory pain relief: suppression of inducible nitric oxide synthase in arthritic
rats</article-title>. <source>Phys Ther</source>, <year>2006</year>,
<volume>86</volume>: <fpage>39</fpage>&#x02013;<lpage>49</lpage>. <pub-id pub-id-type="pmid">16386061</pub-id></mixed-citation></ref><ref id="r21"><label>21</label><mixed-citation publication-type="journal"><person-group><name><surname>Esenyel</surname><given-names>M</given-names></name><name><surname>Caglar</surname><given-names>N</given-names></name><name><surname>Aldemir</surname><given-names>T</given-names></name></person-group>: <article-title>Treatment of myofascial pain</article-title>. <source>Am J
Phys Med Rehabil</source>, <year>2000</year>, <volume>79</volume>:
<fpage>48</fpage>&#x02013;<lpage>52</lpage>. <pub-id pub-id-type="pmid">10678603</pub-id></mixed-citation></ref><ref id="r22"><label>22</label><mixed-citation publication-type="journal"><person-group><name><surname>Draper</surname><given-names>DO</given-names></name><name><surname>Mahaffey</surname><given-names>C</given-names></name><name><surname>Kaiser</surname><given-names>D</given-names></name><etal>et al.</etal></person-group>: <article-title>Thermal ultrasound decreases tissue stiffness of trigger
points in upper trapezius muscles</article-title>. <source>Physiother Theory
Pract</source>, <year>2010</year>, <volume>26</volume>:
<fpage>167</fpage>&#x02013;<lpage>172</lpage>. <pub-id pub-id-type="pmid">20331373</pub-id></mixed-citation></ref><ref id="r23"><label>23</label><mixed-citation publication-type="journal"><person-group><name><surname>M&#x000fc;ller-Ehrenberg</surname><given-names>H</given-names></name><name><surname>Licht</surname><given-names>G</given-names></name></person-group>: <article-title>Medizinisch diagnosis and therapy of myofascial pain
syndrome with focused shock waves</article-title>. <source>Orthop Tech</source>,
<year>2005</year>, <volume>5</volume>:
<fpage>1</fpage>&#x02013;<lpage>6</lpage>.</mixed-citation></ref><ref id="r24"><label>24</label><mixed-citation publication-type="journal"><person-group><name><surname>Speed</surname><given-names>CA</given-names></name></person-group>: <article-title>Extracorporeal shock-wave therapy in the management of
chronic soft-tissue conditions</article-title>. <source>J Bone Joint Surg Br</source>,
<year>2004</year>, <volume>86</volume>: <fpage>165</fpage>&#x02013;<lpage>171</lpage>.
<pub-id pub-id-type="pmid">15046427</pub-id></mixed-citation></ref><ref id="r25"><label>25</label><mixed-citation publication-type="journal"><person-group><name><surname>Mittermayr</surname><given-names>R</given-names></name><name><surname>Hartinger</surname><given-names>J</given-names></name><name><surname>Antonic</surname><given-names>V</given-names></name><etal>et al.</etal></person-group>: <article-title>Extracorporeal shock wave therapy (ESWT) minimizes
ischemic tissue necrosis irrespective of application time and promotes tissue
revascularization by stimulating angiogenesis</article-title>. <source>Ann
Surg</source>, <year>2011</year>, <volume>253</volume>:
<fpage>1024</fpage>&#x02013;<lpage>1032</lpage>. <pub-id pub-id-type="pmid">21372687</pub-id></mixed-citation></ref><ref id="r26"><label>26</label><mixed-citation publication-type="journal"><person-group><name><surname>Wild</surname><given-names>C</given-names></name><name><surname>Khene</surname><given-names>M</given-names></name><name><surname>Wanke</surname><given-names>S</given-names></name></person-group>: <article-title>Extracorporeal shock wave therapy in orthopedics.
Assessment of an emerging health technology</article-title>. <source>Int J Technol
Assess Health Care</source>, <year>2000</year>, <volume>16</volume>:
<fpage>199</fpage>&#x02013;<lpage>209</lpage>. <pub-id pub-id-type="pmid">10815365</pub-id></mixed-citation></ref><ref id="r27"><label>27</label><mixed-citation publication-type="journal"><person-group><name><surname>Haake</surname><given-names>M</given-names></name><name><surname>B&#x000f6;ddeker</surname><given-names>IR</given-names></name><name><surname>Decker</surname><given-names>T</given-names></name><etal>et al.</etal></person-group>: <article-title>Side-effects of extracorporeal shock wave therapy (ESWT)
in the treatment of tennis elbow</article-title>. <source>Arch Orthop Trauma
Surg</source>, <year>2002</year>, <volume>122</volume>:
<fpage>222</fpage>&#x02013;<lpage>228</lpage>. <pub-id pub-id-type="pmid">12029512</pub-id></mixed-citation></ref></ref-list></back></article>